| Description | Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease. |
| In vitro | Copper histidine（10 lmol/L）通过抑制HEK293细胞中过量表达的大鼠Ctr1介导的奥沙利铂的细胞内吸收，从而抑制其活性。[1] |
| molecular weight | 217.69 |
| Molecular formula | C6H8CuN3O2 |
| CAS | 77280-83-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: < 1 mg/mL (insoluble or slightly soluble) (1.97 mM) DMSO: < 1 mg/mL (insoluble） |
| References | 1. Kroepfl T, et al. Copper concentration of liver tissue under long-term copper-histidine therapy in a patient with Menkes disease. J Inherit Metab Dis. 2006;29(4):593. 2. Ip V, et al. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol. 2013;40(6):371-378. |